MedPath

Hemodynamics During Induction of General Anesthesia After Prophylactic Ephedrine, Phenylephrine or Norepinephrine.

Phase 4
Completed
Conditions
Anesthesia, General
Anesthesia, Intravenous
Hemodynamic Instability
Interventions
Registration Number
NCT03864094
Lead Sponsor
Helse Fonna
Brief Summary

In this trial the investigators want to examine if there is any difference in hemodynamic stability when giving equipotent prophylactic injections of ephedrine 0,1 mg/kg, phenylephrine 1 microg/kg, norepinephrine 0,1 microg/kg or sodium chloride (NaCl) 9 mg/ml during induction of general anesthesia with propofol and remifentanil.

Detailed Description

The LiDCOplus monitoring system (Lithium Dilutional Cardiac Output (LiDCO) Ltd., Cambridge, United Kingdom) is a minimally invasive monitor for measuring stroke volume (SV) using two different algorithms. The PulseCO (PulseCO ™, Cambridge, United Kingdom) is based on analyses of the the arterial pressure wave giving nominal values. The LiDCO uses lithium-dilution for calibration to give absolute values. In this trial, the investigators will use the PulseCO looking at relative changes in uncalibrated hemodynamic variables. Continual changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO) and systemic vascular resistance (SVR) will be measured.

Earlier studies have shown that propofol 2.5 mg/kg induction without opioid reduces CO (-15%), SV (-5 %), MAP (-33%) and SVR (-11%) and a slight reduction i HR. High-dose remifentanil anesthesia (2 microg/kg/min), in coronary patients reduced cardiac index (-25%), SV (-14%) and MAP (-39%) in a similar manner as propofol/remifentanil (propofol target 2 microg/ml and remifentanil 0.5 microg/kg/min), but systemic vascular resistance index decreased (-14%) in propofol/remifentanil combination.

Several procedures have been proposed to minimize the negative hemodynamic changes during induction. Administration of a crystalloid or a colloid did not prevent the decrease in MAP after induction of general anesthesia with propofol and fentanyl.

The hemodynamic effects in propofol-fentanyl anesthesia of preoperative ephedrine 0.07-0.15 mg/kg vs phenylephrine 1.5 microg/kg in valve surgery and concludes that ephedrine 0.07-0.1 mg/kg is safe and effective in counteracting hypotension. A dose of 0.15 mg/kg ephedrine is suggested for preventing hypotension during anesthesia induction with propofol 2.5 mg/kg and remifentanil 3 microg/kg.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
128
Inclusion Criteria
  • Healthy women
  • Age 18-50 years
  • Gynecological procedures
  • General anesthesia
Exclusion Criteria
  • Pre-existing hypertension
  • Diabetes for several years
  • Ischemic heart disease
  • Cerebrovascular disease
  • Heart valve disease
  • Verified cardiac arrhythmia
  • Anaemia
  • Kidney or hepatic disease
  • Hypersensitivity for soya, eggs or peanuts
  • Pregnancy
  • Poor health state
  • Illicit substance use
  • BMI <20 or >35 kg/m2
  • SBP >150 mmHg
  • HR >100 beats/min

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ephedrine Propofol RemifentanilEphedrineProphylactic Ephedrine
Ephedrine Propofol RemifentanilPropofolProphylactic Ephedrine
Ephedrine Propofol RemifentanilRemifentanilProphylactic Ephedrine
Phenylephrine Propofol RemifentanilPhenylephrineProphylactic Phenylephrine
Phenylephrine Propofol RemifentanilPropofolProphylactic Phenylephrine
Phenylephrine Propofol RemifentanilRemifentanilProphylactic Phenylephrine
Norepinephrine Propofol RemifentanilNorepinephrineProphylactic Norepinephrine
Norepinephrine Propofol RemifentanilPropofolProphylactic Norepinephrine
Norepinephrine Propofol RemifentanilRemifentanilProphylactic Norepinephrine
Sodium chloride Propofol RemifentanilSodium chlorideNaCl Placebo
Sodium chloride Propofol RemifentanilRemifentanilNaCl Placebo
Sodium chloride Propofol RemifentanilPropofolNaCl Placebo
Primary Outcome Measures
NameTimeMethod
Heart Rate (HR)First 7,5 minutes from start of induction

Change in HR during induction as measured by the LiDCOplus monitoring system

Systolic Blood Pressure (SBP)First 7,5 minutes from start of induction

Change in SBP during induction as measured by the LiDCOplus monitoring system

Secondary Outcome Measures
NameTimeMethod
Stroke Volume (SV)First 7,5 minutes from start of induction

Change in SV during induction as measured by the LiDCOplus monitoring system

Cardiac Output (CO)First 7,5 minutes from a start of induction

Change in CO during induction as measured by the LiDCOplus monitoring system

Systemic Vascular Resistance (SVR)First 7,5 minutes from start of induction

Change in SVR during induction as measured by the LiDCOplus monitoring system

Trial Locations

Locations (1)

Helse Fonna, Haugesund Sykehus

🇳🇴

Haugesund, Norway

© Copyright 2025. All Rights Reserved by MedPath